GEN Exclusives

More »

GEN News Highlights

More »
Jun 20, 2007

Noven Receives $5.9M in ADHD Patch Partnership with Shire

  • Noven Pharmaceuticals reported that Shire has exercised its option to acquire the exclusive development rights to a transdermal patch for ADHD. Noven thus received a $5.9-million milestone payment.

    Noven successfully completed a Phase I study of an amphetamine transdermal system (ATS) for the treatment of ADHD. Shire has requested modifications to the original patch formulation to align ATS, and Noven will be compensated for its continuing development efforts.

    "Noven and Shire have worked collaboratively since 2003 to develop and commercialize patches for ADHD, with Daytrana representing the first patch approved in the category," remarks Jeffrey F. Eisenberg, Noven's senior vp, strategic alliances. "We are very pleased to see this alliance expanded to include a Noven patch expected to be aligned with Shire's ADHD portfolio."

    Shire is the global licensee of Daytrana, a methylphenidate transdermal system for the treatment of ADHD. The drug was developed and manufactured by Noven and launched by Shire in June, 2006. It reportedly is currently the only transdermal product approved for ADHD therapy.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?